407 related articles for article (PubMed ID: 19583774)
1. NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease.
Su XC; Ozawa K; Yagi H; Lim SP; Wen D; Ekonomiuk D; Huang D; Keller TH; Sonntag S; Caflisch A; Vasudevan SG; Otting G
FEBS J; 2009 Aug; 276(15):4244-55. PubMed ID: 19583774
[TBL] [Abstract][Full Text] [Related]
2. Homology modeling and molecular dynamics study of West Nile virus NS3 protease: a molecular basis for the catalytic activity increased by the NS2B cofactor.
Zhou H; Singh NJ; Kim KS
Proteins; 2006 Nov; 65(3):692-701. PubMed ID: 16972281
[TBL] [Abstract][Full Text] [Related]
3. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.
Wichapong K; Pianwanit S; Sippl W; Kokpol S
J Mol Recognit; 2010; 23(3):283-300. PubMed ID: 19693793
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of proteolytically active and highly stable truncated and full-length recombinant West Nile virus NS3.
Chappell KJ; Stoermer MJ; Fairlie DP; Young PR
Protein Expr Purif; 2007 May; 53(1):87-96. PubMed ID: 17174105
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
Erbel P; Schiering N; D'Arcy A; Renatus M; Kroemer M; Lim SP; Yin Z; Keller TH; Vasudevan SG; Hommel U
Nat Struct Mol Biol; 2006 Apr; 13(4):372-3. PubMed ID: 16532006
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the West Nile virus protease substrate specificity and inhibitors.
Mueller NH; Yon C; Ganesh VK; Padmanabhan R
Int J Biochem Cell Biol; 2007; 39(3):606-14. PubMed ID: 17188926
[TBL] [Abstract][Full Text] [Related]
7. Binding of low molecular weight inhibitors promotes large conformational changes in the dengue virus NS2B-NS3 protease: fold analysis by pseudocontact shifts.
de la Cruz L; Nguyen TH; Ozawa K; Shin J; Graham B; Huber T; Otting G
J Am Chem Soc; 2011 Nov; 133(47):19205-15. PubMed ID: 22007671
[TBL] [Abstract][Full Text] [Related]
8. NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease.
Su XC; Ozawa K; Qi R; Vasudevan SG; Lim SP; Otting G
PLoS Negl Trop Dis; 2009 Dec; 3(12):e561. PubMed ID: 19997625
[TBL] [Abstract][Full Text] [Related]
9. STD-NMR experiments identify a structural motif with novel second-site activity against West Nile virus NS2B-NS3 protease.
Schöne T; Grimm LL; Sakai N; Zhang L; Hilgenfeld R; Peters T
Antiviral Res; 2017 Oct; 146():174-183. PubMed ID: 28927677
[TBL] [Abstract][Full Text] [Related]
10. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation.
Robin G; Chappell K; Stoermer MJ; Hu SH; Young PR; Fairlie DP; Martin JL
J Mol Biol; 2009 Feb; 385(5):1568-77. PubMed ID: 19059417
[TBL] [Abstract][Full Text] [Related]
11. Japanese encephalitis virus NS2B-NS3 protease binding to phage-displayed human brain proteins with the domain of trypsin inhibitor and basic region leucine zipper.
Lin CW; Lin KH; Lyu PC; Chen WJ
Virus Res; 2006 Mar; 116(1-2):106-13. PubMed ID: 16289409
[TBL] [Abstract][Full Text] [Related]
12. The active essential CFNS3d protein complex.
Melino S; Fucito S; Campagna A; Wrubl F; Gamarnik A; Cicero DO; Paci M
FEBS J; 2006 Aug; 273(16):3650-62. PubMed ID: 16911516
[TBL] [Abstract][Full Text] [Related]
13. West Nile Virus (WNV) protease and membrane interactions revealed by NMR spectroscopy.
Gayen S; Chen AS; Huang Q; Kang C
Biochem Biophys Res Commun; 2012 Jul; 423(4):799-804. PubMed ID: 22713461
[TBL] [Abstract][Full Text] [Related]
14. Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors.
Knox JE; Ma NL; Yin Z; Patel SJ; Wang WL; Chan WL; Ranga Rao KR; Wang G; Ngew X; Patel V; Beer D; Lim SP; Vasudevan SG; Keller TH
J Med Chem; 2006 Nov; 49(22):6585-90. PubMed ID: 17064076
[TBL] [Abstract][Full Text] [Related]
15. Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway.
Ramanathan MP; Chambers JA; Pankhong P; Chattergoon M; Attatippaholkun W; Dang K; Shah N; Weiner DB
Virology; 2006 Feb; 345(1):56-72. PubMed ID: 16243374
[TBL] [Abstract][Full Text] [Related]
16. Exploring the binding of peptidic West Nile virus NS2B-NS3 protease inhibitors by NMR.
Kang C; Gayen S; Wang W; Severin R; Chen AS; Lim HA; Chia CS; Schüller A; Doan DN; Poulsen A; Hill J; Vasudevan SG; Keller TH
Antiviral Res; 2013 Feb; 97(2):137-44. PubMed ID: 23211132
[TBL] [Abstract][Full Text] [Related]
17. Detection and in-cell selectivity profiling of the full-length West Nile virus NS2B/NS3 serine protease using membrane-anchored fluorescent substrates.
Condotta SA; Martin MM; Boutin M; Jean F
Biol Chem; 2010 May; 391(5):549-59. PubMed ID: 20302513
[TBL] [Abstract][Full Text] [Related]
18. Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics.
Ekonomiuk D; Su XC; Ozawa K; Bodenreider C; Lim SP; Otting G; Huang D; Caflisch A
J Med Chem; 2009 Aug; 52(15):4860-8. PubMed ID: 19572550
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease.
Hammamy MZ; Haase C; Hammami M; Hilgenfeld R; Steinmetzer T
ChemMedChem; 2013 Feb; 8(2):231-41. PubMed ID: 23307694
[TBL] [Abstract][Full Text] [Related]
20. Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor.
Martinez AA; Espinosa BA; Adamek RN; Thomas BA; Chau J; Gonzalez E; Keppetipola N; Salzameda NT
Eur J Med Chem; 2018 Sep; 157():1202-1213. PubMed ID: 30193218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
